A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Insulin glulisine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LixiLan-India
- Sponsors Sanofi
- 05 Dec 2019 Status changed from active, no longer recruiting to completed.
- 10 Apr 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 10 Apr 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.